Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 32345 | 4.2376 |
09:34 ET | 18664 | 4.3 |
09:36 ET | 23898 | 4.3 |
09:38 ET | 14706 | 4.28 |
09:39 ET | 5938 | 4.19 |
09:41 ET | 13300 | 4.1301 |
09:43 ET | 4970 | 4.13 |
09:45 ET | 13331 | 4.0795 |
09:48 ET | 59310 | 4.17 |
09:50 ET | 6399 | 4.195 |
09:52 ET | 8262 | 4.255 |
09:54 ET | 4447 | 4.245 |
09:56 ET | 10800 | 4.245 |
09:57 ET | 13176 | 4.245 |
09:59 ET | 22552 | 4.24 |
10:01 ET | 2591 | 4.245 |
10:03 ET | 23561 | 4.3 |
10:06 ET | 25575 | 4.395 |
10:08 ET | 10600 | 4.355 |
10:10 ET | 9375 | 4.345 |
10:12 ET | 638 | 4.35 |
10:14 ET | 5074 | 4.325 |
10:15 ET | 10754 | 4.42 |
10:17 ET | 10478 | 4.4097 |
10:19 ET | 5242 | 4.345 |
10:21 ET | 3690 | 4.39 |
10:24 ET | 14748 | 4.385 |
10:26 ET | 2118 | 4.385 |
10:28 ET | 9587 | 4.435 |
10:30 ET | 6786 | 4.4272 |
10:32 ET | 6677 | 4.455 |
10:33 ET | 24839 | 4.455 |
10:35 ET | 1800 | 4.455 |
10:37 ET | 86639 | 4.4501 |
10:39 ET | 14227 | 4.425 |
10:42 ET | 13706 | 4.4401 |
10:44 ET | 13470 | 4.405 |
10:46 ET | 3689 | 4.445 |
10:48 ET | 2565 | 4.405 |
10:50 ET | 3500 | 4.425 |
10:51 ET | 5326 | 4.44 |
10:53 ET | 400 | 4.435 |
10:55 ET | 4295 | 4.475 |
10:57 ET | 8396 | 4.48 |
11:00 ET | 1606 | 4.455 |
11:02 ET | 1585 | 4.4506 |
11:04 ET | 2889 | 4.46 |
11:06 ET | 6701 | 4.41 |
11:08 ET | 1202 | 4.4105 |
11:09 ET | 6400 | 4.365 |
11:11 ET | 6621 | 4.365 |
11:13 ET | 5433 | 4.345 |
11:15 ET | 3551 | 4.345 |
11:18 ET | 21443 | 4.345 |
11:20 ET | 23598 | 4.35 |
11:22 ET | 700 | 4.345 |
11:24 ET | 32410 | 4.335 |
11:26 ET | 1050 | 4.34 |
11:27 ET | 4259 | 4.37 |
11:29 ET | 4900 | 4.4 |
11:31 ET | 5612 | 4.415 |
11:33 ET | 1400 | 4.415 |
11:36 ET | 19412 | 4.36 |
11:38 ET | 10253 | 4.35 |
11:40 ET | 1309 | 4.385 |
11:42 ET | 3050 | 4.39 |
11:44 ET | 3768 | 4.405 |
11:45 ET | 2142 | 4.4 |
11:47 ET | 300 | 4.4 |
11:49 ET | 1551 | 4.405 |
11:51 ET | 1883 | 4.39 |
11:54 ET | 1600 | 4.4 |
11:56 ET | 11346 | 4.39 |
11:58 ET | 7900 | 4.375 |
12:00 ET | 600 | 4.38 |
12:02 ET | 1906 | 4.395 |
12:03 ET | 6088 | 4.36 |
12:05 ET | 6817 | 4.3505 |
12:07 ET | 683 | 4.355 |
12:09 ET | 16502 | 4.345 |
12:12 ET | 12588 | 4.36 |
12:14 ET | 5341 | 4.37 |
12:16 ET | 16211 | 4.36 |
12:18 ET | 3927 | 4.36 |
12:20 ET | 900 | 4.365 |
12:21 ET | 3633 | 4.385 |
12:23 ET | 714 | 4.39 |
12:25 ET | 2800 | 4.395 |
12:27 ET | 758 | 4.4 |
12:30 ET | 700 | 4.4 |
12:32 ET | 4195 | 4.375 |
12:34 ET | 800 | 4.375 |
12:36 ET | 3742 | 4.365 |
12:38 ET | 300 | 4.365 |
12:39 ET | 100 | 4.365 |
12:41 ET | 5203 | 4.395 |
12:43 ET | 368 | 4.395 |
12:45 ET | 548 | 4.395 |
12:48 ET | 322 | 4.4 |
12:50 ET | 2700 | 4.399 |
12:52 ET | 900 | 4.395 |
12:54 ET | 300 | 4.395 |
12:56 ET | 772 | 4.3907 |
12:57 ET | 1700 | 4.395 |
12:59 ET | 3562 | 4.365 |
01:01 ET | 1509 | 4.39 |
01:03 ET | 1600 | 4.3896 |
01:06 ET | 4707 | 4.36 |
01:08 ET | 600 | 4.365 |
01:10 ET | 100 | 4.365 |
01:12 ET | 100 | 4.365 |
01:14 ET | 3600 | 4.365 |
01:15 ET | 700 | 4.365 |
01:17 ET | 2484 | 4.38 |
01:19 ET | 100 | 4.39 |
01:21 ET | 1755 | 4.3789 |
01:24 ET | 200 | 4.375 |
01:26 ET | 7721 | 4.365 |
01:28 ET | 511 | 4.365 |
01:30 ET | 400 | 4.36 |
01:32 ET | 400 | 4.3602 |
01:33 ET | 2500 | 4.365 |
01:35 ET | 11451 | 4.37 |
01:37 ET | 4100 | 4.38 |
01:39 ET | 17098 | 4.39 |
01:42 ET | 12127 | 4.4 |
01:44 ET | 11888 | 4.3601 |
01:48 ET | 1700 | 4.3601 |
01:50 ET | 600 | 4.3614 |
01:51 ET | 100 | 4.365 |
01:53 ET | 4300 | 4.365 |
01:55 ET | 500 | 4.365 |
01:57 ET | 200 | 4.365 |
02:00 ET | 400 | 4.365 |
02:02 ET | 6022 | 4.3675 |
02:04 ET | 400 | 4.365 |
02:06 ET | 433 | 4.365 |
02:08 ET | 1586 | 4.365 |
02:09 ET | 2293 | 4.3606 |
02:11 ET | 1805 | 4.365 |
02:13 ET | 500 | 4.365 |
02:15 ET | 1158 | 4.3638 |
02:18 ET | 43372 | 4.385 |
02:20 ET | 214 | 4.385 |
02:22 ET | 100 | 4.39 |
02:24 ET | 1078 | 4.39 |
02:26 ET | 100 | 4.385 |
02:27 ET | 1826 | 4.385 |
02:29 ET | 500 | 4.385 |
02:31 ET | 2900 | 4.385 |
02:33 ET | 1000 | 4.385 |
02:36 ET | 13739 | 4.355 |
02:38 ET | 26785 | 4.33 |
02:40 ET | 1048 | 4.335 |
02:42 ET | 2599 | 4.35 |
02:44 ET | 1980 | 4.3575 |
02:45 ET | 1300 | 4.36 |
02:47 ET | 700 | 4.355 |
02:49 ET | 3285 | 4.345 |
02:51 ET | 2100 | 4.345 |
02:54 ET | 10706 | 4.335 |
02:56 ET | 400 | 4.335 |
02:58 ET | 2498 | 4.335 |
03:00 ET | 1305 | 4.335 |
03:02 ET | 800 | 4.335 |
03:03 ET | 4147 | 4.335 |
03:05 ET | 1207 | 4.335 |
03:07 ET | 1560 | 4.335 |
03:09 ET | 13811 | 4.38 |
03:12 ET | 17403 | 4.375 |
03:14 ET | 23282 | 4.405 |
03:16 ET | 2600 | 4.41 |
03:18 ET | 14373 | 4.365 |
03:20 ET | 4978 | 4.3601 |
03:21 ET | 9981 | 4.345 |
03:23 ET | 200 | 4.345 |
03:25 ET | 1800 | 4.345 |
03:27 ET | 8529 | 4.345 |
03:30 ET | 1352 | 4.345 |
03:32 ET | 2200 | 4.345 |
03:34 ET | 9206 | 4.345 |
03:36 ET | 2458 | 4.345 |
03:38 ET | 1500 | 4.345 |
03:39 ET | 1400 | 4.345 |
03:41 ET | 1934 | 4.345 |
03:43 ET | 3520 | 4.345 |
03:45 ET | 3128 | 4.345 |
03:48 ET | 5518 | 4.35 |
03:50 ET | 5907 | 4.345 |
03:52 ET | 23778 | 4.37 |
03:54 ET | 30504 | 4.385 |
03:56 ET | 53504 | 4.385 |
03:57 ET | 51551 | 4.385 |
03:59 ET | 297734 | 4.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.1B | -2.9x | --- |
Apogee Therapeutics Inc | 3.1B | -31.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
MoonLake Immunotherapeutics | 2.9B | -59.4x | --- |
IDEAYA Biosciences Inc | 3.2B | -21.5x | --- |
Xenon Pharmaceuticals Inc | 3.3B | -16.0x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.28 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.